CareCloud, Inc. 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock - CCLDO STOCK NEWS

CareCloud (CCLD) reports encouraging trends in the voting on its Series A Preferred Stock proposal. 72% of Series A Preferred Shares that have returned proxies to date approve the Preferred Stock Proposal. The company needs an affirmative vote of at least two-thirds of all outstanding Series A Preferred Stock (about 3 million of 4.5 million shares) for the proposal to pass.

If approved, the proposal would grant Series A Preferred Stockholders similar change of control protections as Series B Preferred Stockholders, align the dividend with Series B Preferred Stock, and allow CareCloud to exchange Series A Preferred Stock for common stock at the $25/share liquidation preference value plus accrued dividends. The voting deadline is August 21, 2024.

CareCloud, Inc. (Nasdaq: CCLD) has expanded its partnership with DrFirst to include RxInform functionality, aimed at improving medication adherence and reducing healthcare costs. This integration enhances CareCloud's platform by:

1. Addressing financial challenges through notifications and coupons for patients
2. Offering a seamless notification system for prescription updates
3. Providing text alerts throughout the prescription process
4. Incorporating coupons and discount cards to alleviate financial burdens

The partnership aims to reduce prescription abandonment, improve patient engagement, and ultimately lead to better health outcomes. DrFirst's RxInform has maintained a 95% satisfaction rate based on over 20 million patient ratings.

CareCloud (Nasdaq: CCLD) announced an amendment proposal for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock. The proposal seeks to align the terms of Series A Preferred Stock with those of the 8.75% Series B Preferred Stock. If approved, Series A stockholders would gain change of control protections, a reduced 8.75% dividend rate, and an optional exchange feature. The amendment requires a two-thirds majority approval from Series A shareholders. The Special Meeting is scheduled for August 23, 2024, with proxies being solicited starting July 8, 2024. These changes aim to better position shareholders for potential future transactions and enhance value.

CareCloud announced the results of its 2024 Annual Shareholder Meeting held on June 17, 2024. Shareholders re-elected A. Hadi Chaudhry, John Daly, Mahmud Haq, and Cameron Munter as directors with over 90% approval. Additionally, shareholders approved the compensation for the company's named executive officers as outlined in CareCloud's 2024 Proxy Statement. The meeting's outcomes were filed in a Form 8-K with the SEC. Executive Chairman Mahmud Haq expressed gratitude for the support from shareholders, customers, and employees, and highlighted the company's goals to grow free cash flow, expand AI solutions, and increase the customer base.

CareCloud (Nasdaq: CCLD) announced that CEO Hadi Chaudhry and President Stephen Snyder will discuss the use of generative AI in healthcare. The discussion will take place in a fireside chat on June 4, 2024, during a virtual conference hosted by Maxim Group. CareCloud serves 2,600 physician practices across the U.S., and the leadership will highlight how generative AI can enhance healthcare services and operational efficiencies. The event aims to explore AI's broader impact on the healthcare industry.

CareCloud has promoted Crystal Williams to Chief Operating Officer (COO), effective May 21, 2024. Williams brings over 20 years of experience in revenue cycle management (RCM) and was previously VP of Client Operations at CareCloud. She aims to streamline operations and enhance profitability. Williams' prior roles include leadership positions at GE Healthcare, where she led initiatives to improve efficiencies, margins, and client revenue. This strategic move is intended to leverage CareCloud's global operations for better client experiences and patient outcomes.

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) announced its Q1 2024 financial results, reporting $26 million in revenue, down from $30 million in Q1 2023.

Despite lower revenue, the company achieved a GAAP operating income of $129,000, compared to a $223,000 loss in the previous year.

Net loss improved to $241,000 or $0.02 per share, from $401,000 or $0.28 per share in Q1 2023. Adjusted EBITDA fell to $3.7 million from $4.2 million, but cash from operations surged to $4.1 million from $1.0 million, and free cash flow reached $2.2 million, a significant improvement from a negative $2.0 million in Q1 2023.

Operationally, CareCloud identified $22 million in annualized expense reductions, with $15 million expected this year, and repaid $2 million of its credit facility.

The company is also leveraging generative AI to enhance efficiencies. CEO A. Hadi Chaudhry expressed optimism about the financial direction, highlighting improvements in cash flow metrics and profitability.

CareCloud, Inc. received an unsolicited offer to acquire the company for $5.00 per share of common stock and $25 redemption price per share of its Series B Preferred Stock. The Board of Directors declined the offer after thorough evaluation and retained an investment bank to assess the terms of its Series A Preferred Stock.

CareCloud, Inc. has retained Citizens JMP as its exclusive capital structure advisor after receiving an unsolicited indication of interest to acquire the company. The Board of Directors declined the proposal and Citizens JMP will evaluate CareCloud's capital structure for potential modifications to its Series A Preferred Stock.